Last reviewed · How we verify

antiperspirant cream F511 — Competitive Intelligence Brief

antiperspirant cream F511 (antiperspirant cream F511) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Dermatology.

phase 3 Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

antiperspirant cream F511 (antiperspirant cream F511) — Swiss Cancer Institute. Antiperspirant cream F511 reduces sweat production by blocking eccrine sweat gland activity, likely through aluminum salt-based or similar astringent mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
antiperspirant cream F511 TARGET antiperspirant cream F511 Swiss Cancer Institute phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). antiperspirant cream F511 — Competitive Intelligence Brief. https://druglandscape.com/ci/antiperspirant-cream-f511. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: